Regena.com - Site Name Reserved
Madison Partners LLC – Investment Strategies
Description: Regenacy Pharmaceuticals is a pioneer in developing novel treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme ("HDAC") inhibitors.
LATEST NEWS 8.24.22 - REGENACY PHARMACEUTICALS ANNOUNCES COMPLETION OF ENROLLMENT FOR PHASE 2 STUDY IN DIABETIC PERIPHERAL NEUROPATHY & $9.3 MILLION SERIES B FINANCING
Our lead compound ricolinostat (ACY-1215) is an oral, selective inhibitor of the microtubule modifying enzyme HDAC6 with first-in-class potential, that will be entering a proof-of-concept (PoC) Phase 2 clinical trial in diabetic peripheral neuropathy. Our investigation of ricolinostat for diabetic, chemotherapy-induced, and inherited peripheral neuropathies is based on compelling PoC preclinical studies demonstrating restoration of normal nerve function.
We were founded in December 2016 following the acquisition of Acetylon Pharmaceuticals by Celgene. Regenacy received exclusive rights to ricolinostat, a clinical stage, orally bioavailable, HDAC6 selective inhibitor, for a range of non-cancer disease indications. We also have a unique and proprietary portfolio of selective HDAC1,2 inhibitors with potential for treating cancer, hemoglobinopathies, and cognitive dysfunction.
Regena.com - Site Name Reserved
Madison Partners LLC – Investment Strategies